ViCentra Appoints Diabetes Commercialization Leader Reman McDonagh as Vice President, Global Marketing [Yahoo! Finance]
Insulet Corporation (PODD)
Last insulet corporation earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insulet.com/investor-relations
Company Research
Source: Yahoo! Finance
UTRECHT, the Netherlands Jan. 29, 2026 /PRNewswire/ -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced today that Reman McDonagh, PhD, has joined the Company as Vice President, Global Marketing. McDonagh's appointment further strengthens ViCentra's leadership team as the company scales commercial execution across Europe and advances preparations for its next-generation Kaleido system, including EU and U.S. launches. McDonagh brings more than 20 years of experience in diabetes and medical device commercialization, spanning early-stage innovation through large-scale international growth. She has held leadership roles at Roche, Medtronic, Cellnovo, and Insulet, with responsibility across brand strategy, go-to-market planning, market development, and major product launches in both established and high-growth markets. Her appointment builds on ViCentra's strong commercial and operational momentum, supported by the company's
Show less
Read more
Impact Snapshot
Event Time:
PODD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PODD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PODD alerts
High impacting Insulet Corporation news events
Weekly update
A roundup of the hottest topics
PODD
News
- Insulin Pump Market Insights $2.1B Revenue from Insulet, 500,000+ U.S. Users and 47.8% Adoption in Canada Driven by Government Funding [Yahoo! Finance]Yahoo! Finance
- Insulet Launches Omnipod® 5 and Omnipod Discoverâ„¢ in the Middle East to Transform Diabetes CareBusiness Wire
- Insulet (NASDAQ:PODD) had its price target lowered by analysts at Stifel Nicolaus from $370.00 to $350.00. They now have a "buy" rating on the stock.MarketBeat
- Insulet Corporation (PODD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Reasons Why Hedge Funds Favor Insulet Corp (PODD) [Yahoo! Finance]Yahoo! Finance
PODD
Earnings
- 11/6/25 - Beat
PODD
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/3/26 - Form 8-K
- 1/6/26 - Form 4
- PODD's page on the SEC website